Multiple Endocrine Neoplasia Type 2a (MEN 2)

A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.
Also Known As:
MEN 2; MEN II; Multiple Endocrine Neoplasia Type 2; MEA 2a; MEA II; MEA IIa; MEN IIa; MEN-2A Syndrome; MEN2a; Multiple Endocrine Neoplasms Type 2a; MEN 2A Syndrome; MEN-2A Syndromes; MEN 2a; Neoplasia, Multiple Endocrine Type 2a; Neoplasms, Multiple Endocrine Type 2a; Sipple Syndrome
Networked: 1037 relevant articles (17 outcomes, 78 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pheochromocytoma
2. Neoplasms (Cancer)
3. Multiple Endocrine Neoplasia Type 2b (MEN 3)
4. Multiple Endocrine Neoplasia Type 2a (MEN 2)
5. Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis)


1. Pacak, Karel: 14 articles (04/2015 - 02/2003)
2. Takahashi, M: 10 articles (04/2014 - 01/2000)
3. Eisenhofer, Graeme: 10 articles (05/2012 - 08/2005)
4. Iwashita, T: 8 articles (04/2014 - 01/2000)
5. Santoro, Massimo: 8 articles (08/2013 - 06/2002)
6. Takahashi, Masahide: 8 articles (05/2010 - 04/2002)
7. Dralle, Henning: 7 articles (01/2012 - 12/2002)
8. Linehan, W Marston: 7 articles (03/2011 - 06/2005)
9. Pacak, K: 7 articles (04/2009 - 05/2001)
10. Wells, Samuel A: 6 articles (10/2015 - 09/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Multiple Endocrine Neoplasia Type 2a:
1. DNA (Deoxyribonucleic Acid)IBA
2. Pentagastrin (Peptavlon)FDA Link
3. Calcitonin (Calcitonin, Eel)FDA LinkGeneric
4. Codon (Codons)IBA
5. Factor IX (PTC)FDA LinkGeneric
6. Insulin (Novolin)FDA Link
07/01/1996 - "Furthermore, insulin suppression of FFAs improved with age in men (2% per decade, P < 0.0001) but not in women. "
01/01/1996 - "In conclusion, insulin-mediated MSNA: 1) is neither a response to nor a cause of the vasodilation observed in insulin sensitive men, 2) has no net pressor effect even in the most insulin resistant men in whom insulin-mediated vasodilation was impaired. "
05/01/1992 - "We investigated the sensitivity to insulin with a hyperinsulinemic (approximately 719 pM [approximately 100 microU/ml]) euglycemic clamp in two groups of normotensive nonproteinuric IDDM patients; 12 (10 men, 2 women) had high Na+/Li+ CT activity (mean 0.47, range 0.42-0.68 mmol/L red blood cells [RBC]/h, group 1) and 12 (9 men, 3 women) had normal Na+/Li+ CT activity (mean 0.24, range 0.12-0.31 mmol/L RBC/h, group 2). "
05/01/1990 - "We conclude that: 1) after ingesting 75 g glucose, normal women showed greater glucose uptake per unit muscle mass than normal men, 2) for 3 hours after the ingestion of 75 g glucose, the predominant tendency toward utilizing glucose by a nonoxidative pathway is more marked in normal women than in normal men, and 3) the higher glucose uptake per unit muscle mass in the female group in the presence of an insulin response not significantly different from that of the male group suggests that muscle insulin sensitivity is greater in normal women."
06/01/2000 - "It is concluded that (1) the athletes have more adequate compensation for the bed-rest-induced decrement in insulin sensitivity than sedentary men; (2) three-day bed rest diminishes basal sympathetic activity and attenuates sympathoadrenal response to oral glucose; (3) endurance athletes have greater sympathetic inhibition than strength athletes or sedentary men."
7. SeleniumIBA
8. Granulocyte Colony-Stimulating Factor (G-CSF)IBA
9. Vincristine (Oncovin)FDA LinkGeneric
10. Mitoxantrone (Novantrone)FDA LinkGeneric

Therapies and Procedures

1. Thyroidectomy
2. Adrenalectomy
3. Transplantation (Transplant Recipients)
4. Drug Therapy (Chemotherapy)
5. Kidney Transplantation